Purpose: Targeting the PD-1/PD-L1 pathway has emerged as a novel therapy for cancer. To identify rational candidates for anti-PD-1/PD-L1 immunotherapy in gastric cancer (GC), the abundance of PD-L1 expression was evaluated on a kind of biomarker-based molecular classification for shaping prognosis and treatment planning. Methods: One hundred and sixty-five GCs were classified into five subgroups using immunohistochemistry (IHC) and in situ hybridization (ISH) methods, based on a panel of seven markers (MLH1, PMS2, MSH2, MSH6, E-cadherin, P53, and Epstein-Barr virus mRNA). The expression of PD-L1 in GC tissues was analyzed immunohistochemically. Results: The five categories (Epstein-Barr virus positivity, microsatellite instability, aberrant E-cadherin, aberrant P53 expression, and normal P53 expression) correspond to the reported molecular subgroups for similar proportions and clinicopathologic characteristics. Survival analysis indicated that subgroups with aberrant E-cadherin expression independently predicted a worse prognosis in GC patients (HR=2.51, P=0.010). The clinical and prognostic profiles produced by this stratification in nonintestinal-type GC were distinguishable from those in intestinal-type. Although PD-L1 was not a significant prognostic factor, that more frequent presence of PD-L1-positive in microsatellite instability tumors than other subtypes (P<0.010) hinted at a prolonged clinical course. Moreover, the lowest level of PD-L1 but the highest of Her2 was observed in the group of aberrant P53, namely it was suggested that there was a negative correlation between PD-L1 and Her2 overexpression. Conclusion: Different molecular subtypes in GC may have a tendency to react differently to anti-PD-L1/PD-1 immunotherapy or anti-Her2 therapy. A combination of PD-L1 expression and this cost-effective classification strategy would be helpful for predicting prognosis and promoting personalized therapy in clinical practice.
Introduction
Gastric cancer (GC) is the third leading cause of cancer-related death worldwide, with a particular high occurrence and mortality in Asia. 1 Although there have been considerable advances in diversified therapeutics over the past decades, the 5-year survival rate of GC after treatment with curative intent is still under 40%. [2] [3] [4] This disappointing outcome is usually caused by the limited capability to discern subpopulations in a heterogeneous cohort of GC patients for differential individualized therapy. Long-term used Lauren and WHO classifications are both merely based on morphologic features and far from disclosing molecular alterations about the complex and diverse biology of GC. 5 Recently, the Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) successively established classification systems of GC via comprehensive molecular analysis. 6, 7 Concretely, TCGA identified Epstein-Barr virus (EBV), microsatellite instability (MSI), chromosomal instability (CIN), genome stable (GS), and ACRG recognized MSI, microsatellite stable/epithelial to mesenchymal transition (MSS/EMT), MSS/TP53-(tumor protein 53 inaction), and MSS/TP53+ (tumor protein 53 activation). Even if such milestone classification greatly broadens our insights into the hidden molecular nature of GC, the demand for expensive and sophisticated high-throughput analysis technologies obviously prevents their clinical application. To overcome this, two research teams proposed an integrated classification contained five molecular subtypes through using relatively inexpensive and widely available immunohistochemistry (IHC) and in situ hybridization (ISH). 8, 9 Intriguingly, despite nearly uniform markers and assessment standards adopted by them in grouping, the clinical utility of this protein and mRNA expression-based stratification is doubtful as there was a huge difference in outcome prediction. Thus, a validation study of TCGA, ACRG, and integrated classification in a cohort of Chinese GC patients was implemented to systematically estimate the predicting value of this simplified molecular classification.
More importantly, what implications for current treatment strategies brought by this simplified approach is still unclear, therefore, it is imperative to combine such molecular classification with novel targets for therapy in GC. The blockade of PD-1 (program death-1)/PD-L1 (programdeath ligand-1) interaction to restore T-cell activity has emerged as a promising therapeutic avenue against various cancer types. 10, 11 It is increasingly acknowledged that PD-L1 as a potential predicative marker of response to immune checkpoint inhibition, which nonetheless only occur in a fraction of PD-L1-positive patients. 12, 13 Some impressive clinical trials of PD-1 inhibitor treatment for solid tumors uncovered that patients with mismatch repair-deficient (d-MMR) have a better prognosis than with mismatch repair-proficient (p-MMR). 14- 16 Hence, it is rational to speculate that GC with d-MMR and PD-L1 expression may be the prime choice for such therapy, guiding us special focus on the allocation of PD-L1 expression for molecular subtypes. Besides that, it is very attractive to identify the relationship between PD-L1 expression and clinical outcomes, owing to its prognostic relevance in GC still being a controversial issue. [17] [18] [19] [20] [21] [22] [23] [24] The time of follow-up was from initial diagnosis to September 2017 (range from 6-76 months).
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Clinicopathologic characteristics and survival analysis in relation to patients' stratification
One hundred and sixty-five GC cases were in turn subdivided by TCGA, ACRG, and integrated classification based on staining results, using the streamlined, stepwise classification algorithm as previously advised ( Figure 1 ). Figure 2 . Clinicopathologic characteristics of integrated classification are summarized in Table S1 (data of TCGA and ACRG was not shown). C1 were both characterized by younger age, large size (≧5cm), poor differentiation, diffuse-type, and proximal stomach. Compared with the rest, C2 was detected to be significantly more prevalent in elderly age (P=0.009) and early TNM stage (P=0.027), especially for stage Ⅱ (P=0.004). Increased frequency but no significant difference was made for C2 in tumors with antrum-located location, tubular-type, medullary carcinoma and low lymph node involvement than the others (71.4% vs 52.1%, 61.9% vs 47.2%, 9.5% vs 1.4%, and 38.1% vs 17.4%). In younger patients (P=0.007), poorly cohesive type (P=0.002) and lesions with T4 stage (P=0.037), more frequent presence of C3 was observed than the remaining cases. C3 also had trends toward diffuse type and higher TNM staging (59.4% vs 44.3% and 75% vs 57.1%), although these differences were not significant. An analogous increased proportion of intestinal-type against the others could be yielded in C4 and C5 (13.4% and 11.3%). Clinicopathologic features and biomarker results for integrated classification are shown in Figure 3 .
Due to a small number of EBV-positive GC, we ruled out them and performed a survival analysis on the remainder (Figures 4A-C). Substantial overall survival (OS) difference stratified by integrated classification was described here (P<0.01): C5 (MSS/TP53+) tumors had the best prognosis and C2 (MSI) had almost the same and slight female dominance (P=0.054) in C5, C2 was inclined to have the best prognosis without prognostic significance ( Figures 4D and E , Figure S1 and Table S2 ). Figure 6 ). Apart from all cases of medullary carcinoma having aberrantly expressed PD-L1 (IC P=0.018, TC/IC P=0.050), the clinical and prognostic relevance failed to reach any significance for such PD-L1 staining patterns (Table 2, Figure 6 ). There still seemed to be an inclination towards better outcomes for those with PD-L1-IC or -TC/IC positivity. When the cut-off defining PD-L1-IC positivity was raised to 5%, there was a more pronounced tendency for PD-L1-IC expressed patients to have a favorable prognosis (IC P=0.067). Among 165 GC cases, the most common category of Her2 overexpression was C4 (11/79, 13.9%) followed by C5 (4/31, 12.9%), whereas C2 (2/21, 9.5%) and C3 (1/32, 3.1%) were less common for Her2 positive, and C1 (0/2) had no Her2 positivity. The CIN subgroup (including C4 and C5) had increased Her2-positive (13.6% vs 5.5% in the remaining cases). Further analysis unveiled that PD-L1 was more frequently expressed in Her2-negative GC than that in Her2-positive GC (TC/IC 42.2% vs 22.2%, TC 11.6% vs 0%, IC 38.8% vs 22.2%), even though no statistical significance was reached.
Distribution of PD-L1-and
Discussion
Increased PD-L1 expression has been associated with clinical activity of anti-PD-1/PD-L1 treatments; however, only a small proportion of PD-L1 expressed patients can truly benefit from checkpoint blockade. In-depth analysis of one-to-one correlations between immune response and molecular or morphological alterations may be a helpful way in selecting patients for PD-1/PD-L1 targeted therapy. Recent clinical trials in a variety of solid tumors (mainly in colorectal cancer) demonstrated a striking difference between d-MMR/MSI-H and p-MMR/MSS in therapeutic response to PD-1/PD-L1 inhibitors. 14-16 Furthermore, MSI immune subtype, as one of the four known molecular subtypes for colorectal cancer, presents with a unique histological characteristics (including mucinous and medullary histology) and aggregated expression of PD-L1.
29-31
As for GC, most previous studies focused on investigating the role of PD-L1 expression in predicting outcomes, but few evaluated PD-L1 expression in the context of molecular classification. How to choose the right patients for anti-PD-1/PD-L1 therapy, anti-Her2 therapy, or others is a thoughtful question with the development of novel therapy strategies. In addition, clinical applications of DNA sequencing technologies are thwarted by the restriction that such methodologies may be inaccessible in many small-scale medical centers and unaffordable by many cancer patients. In this sense, the use of IHC and ISH approaches to assess molecular genetic changes has become a powerful tool in biomarker detection. Accordingly, elucidating the association of PD-L1 expression and molecular subtypes as well as Her2-positive, is key to assess prognostic significance and improve therapy selectivity and efficacy for GC patients. In order to more accurately delineate the expression of PD-L1 on GC tissues, whole tissue sections were adopted to minimize intratumoral heterogeneity. In this patient cohort, 40% of patients had PD-L1 expression on either TC or IC that conform to 8.8-74.9% of PD-L1 positivity in GC reported by previous literature. 17, 18, 20, [22] [23] [24] In contrast with some other research which reported that PD-L1 status could correlate with either favorable or unfavorable prognosis of cancer patients, no significant association was found between PD-L1-positive and almost all clinical and pathologic factors in this study (including TNM staging and OS). Indeed, this is in agreement with both Ma et al 17 and Wang et al, 18 who have published research results that PD-L1 expression is not predictive of patient survival in GC. It should be noted that PD-L1 positivity could vary with antibody clone, preparation of tissue samples, evaluating system, and even geographical differences of recruited patients, leading to discrepant results about the association of PD-L1 expression and prognosis. However this study showed that PD-L1 expression tended to give better survival for GC patients, reminding us not to overlook its distribution on molecular subgroups. Herein, a validation study to assess the reliability of a simplified classification and focused on its prognostic significance in GC patients was then conducted. EBV-positive tumors (8.8% in TCGA; C1) represented a lower incidence of 1.2% in our cohort compared to other literature (2-20%). 8, 9, 32, 33 Such distinction appeared to be caused by either the lower proportion of intestinal-type that are one major histological type of EBV GC, or low diagnosis rate of enrolled early-stage GC (EGC) patients. results will be seen in our subsequent study (the conformity rate is 95.8%). Beyond that, lesser aggressiveness characteristics in parallel with longer survivals were observed in this group, as previously reported. 36, 37, 39, 40, 42 Both TCGA and ACRG defined a distinctive subset characterized by the lowest number of mutation events, named GS (19.7%) and MSS/ EMT (15.3%), respectively. 6, 7 In this study, the malignant features and bad prognosis possessed by C3 tumors (correspondence to GS or MSS/EMT subtypes; 19.4%) were basically identical to those in a Korean trial. 8 The largest subtype described by TCGA is the CIN group (49.8%) that has high frequency of TP53 mutation, corresponding to the subtype of MSS/TP53-(35.7%) in ACRG. 6, 7 Likewise, patients with C4
(MSS/TP53-) and CIN tumors having prediction of intermediate outcomes constituted the biggest part of our entire cohort (66.7% and 47.9%, respectively). The remaining MSS tumors without TP53 mutation fell into the subtype of C5 (18.8% in our cohort) or MSS/TP53+ (26.3% in ACRG).
Unlike the results obtained from research teams in Korea, the present study showed that the prognosis of patients in C5 was slightly superior to that in C2 and yet differed little between them (P=0.704). 7, 8 This difference may be attributed to our overall lower percentage of intestinal-type GC (42.4%), in comparison with the study of Ahn et al 8 
(57%). Hence, it is
vital to further analyze the molecular subtypes in two different Lauren type settings. As expected, the "two-faced" character was substantiated by separate analysis of molecular subtypes in intestinal-and nonintestinal-type GC, especially when considering prognosis. Evidently, additional welldesigned trials are needed to clarify the selective role of Lauren type on molecular classification. Certainly, other critical factors, for example the addition of adjuvant chemotherapy after surgery, may also improve the prognosis of C5 patients, so that further research on the relationship of the prognosis and post-operative therapy within subtypes is very necessary.
In light of the feasibility of using this stratification to reflect approximate molecular alternations, the differential expression of PD-L1 in each molecular subtype of this classification was further investigated. It was shown that PD-L1 was expressed at the highest in C2, followed by C1, which was identical to recent molecular studies having disclosed their altered immune status to some extent. EBVpositive tumors exhibit extreme DNA hypermethylation, high mutation rate of PIK3CA and ARID1A, and frequent amplification of JAK2 and PD-L1/2. 6 And mutational "hotspots" within targetable genes (eg, PIK3CA, ERBB2, ERBB3, EGFR, ARID1A, KRAS, and ALK) are noted in MSI tumors. 16, 17 These hypermutated genes harbored by this class are suggested as the incentive of added number of tumor-specific neoantigens, which might shape response to immunotherapy through enhancing the host's immune system. 6, 7 The finding that PD-L1 positivity with a preference for C2 and C1 was also equal to a previously described elevated PD-L1 expression enriched in MSI and EBV subgroups of GC. 17 Moreover, an exciting clinical response to PD-1 blocking therapy exited in MSI and EBV subgroups of mGC (metastatic GC) patients was verified in another recent study. 43 As such, this simplified classification could be a useful aid to prioritization of anti-PD-1/PD-L1 therapy in these two subgroups of GC patients, especially for C2. Marked amplifications of the RTK-RAS signaling pathway (eg, ERBB2, EGFR, VEGFA, c-MET, FGFR2, and K-RAS) reported by TCGA are reviewed as actionable targets in CIN tumors. 6 In line with previous studies, we found increased Her2 overexpression in C4 (MSS/TP53-) and CIN tumors, but not to a statistical difference. 8, 43 It was of interest that reduced expression of PD-L1 was seen in C4 (MSS/TP53-) and CIN compared to other subtypes, suggesting the Her2 inhibitor was superior to the PD-1/PD-L1 blockade as the possible first-line targeted therapy for C4 (MSS/TP53-)/CIN patients. In fact, the relationship of PD-L1-and Her2-positive remains elusive. Oki et al 44 found a positive relation between them; on the contrary, a negative relation was reported by both Wang et al 18 and Li et al. 21 In current research, the greater difference of PD-L1 expression between patients with or without Her2 overexpression confirmed that immunotherapy may be more suitable for the majority of GC patients who have Her2-negative cancer (89.1% in this study, 77.9-88% in previous studies). 18, 45, 46 Other forceful unconventional treatment methods rather than just anti-PD-1/PD-L1 or antiHer2 therapy should be explored to improve the gloomy prognosis of C3 patients (with a lower prevalence of both PD-L1-and Her2-positive). Notably, some molecular alterations are still found, including the maximum percentage of CDH1 mutation, an increase in RHOA mutation and CLDN18-ARHGAP26 fusion, which might be used for the development of new molecular targets for "neutral" C3 tumors. 6, 7, 47, 48 One major limitation of this study is that TMA slides fail to entirely account for the intratumoral heterogeneity in stratified patients and intricate molecular changes tend to be underestimated by protein expression. For example, one of the two EBV-positive cases with unusual overlapping EBV+ and d-MMR was rectified as p-MMR/MSS both by subsequent MMR IHC (using corresponding whole section) and PCRbased MSI assay. Although this correction did not affect the above results of stepwise stratification, two important things should be mentioned here. The first of these two situations (EBV positive and d-MMR/MSI-H status) are virtually mutually exclusive, similar to previous reports. 6, 43, 49 The second, in order to solve the shortage of TMA methods in correctly reflecting MMR heterogeneity. A more comprehensive categorization of existing approaches will, therefore, be put forward on the whole histological section. At the same time, improving this multi-biomarker panel and enlarging the sample size is another indispensable step for making this stratification closer to actual molecular subtypes and assessing the definite role of PD-L1 expression in GC.
The well-corroborated results from our study elucidates that this protein and mRNA-based classification can be employed as not only a surrogate for molecular subtyping, but also predicting the prognosis of GC. What's more, PD-L1 expression is positively associated with C2/ d-MMR status and negatively associated with C4/Her2-positive, but not predictive of the survival of patients. This classification presents constructive suggestions for different therapeutic directions in GC patients, that is, C2/ d-MMR and C4 (MSS/TP53-)/CIN are the good candidates for anti-PD-1/PD-L1 immunotherapy and anti-Her2 targeted therapy, respectively. In brief, our results highlight this reproducible and affordable stratification strategy, combined with therapy-related biomarkers, can be deemed as a preliminary guideline to optimize GC patients for individualizing treatments. Abbreviations: C1, cluster 1; C2, cluster 2; C3, cluster 3; C4, cluster 4; C5, cluster 5; GEJ, esophagogastric junction.
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